CDK4/6 inhibitors and antiprogestins: therapeutic combination in breast cancer experimental models with high levels of progesterone receptor isoform A

Autores
Pataccini, Gabriela; Vanzulli, Silvia; Lanari, Claudia Lee Malvina; Giulianelli, Sebastian Jesus
Año de publicación
2021
Idioma
inglés
Tipo de recurso
documento de conferencia
Estado
versión publicada
Descripción
Luminal breast cancers are susceptible to an endocrine therapy. Palbociclib (PALBO), a CDK 4/6 inhibitor, is cur-rently used in combination with endocrine therapy to treat advanced hormone receptor-positive breast cancer (BC). However, with time patients acquire resistance. Therefore, alternative therapies are required to reduce BC mortality. We have recently reported that BC patients with tumors expressing higher levels of isoform A of the progesterone re-ceptor (PRA) than isoform B (PRB) may benefit from an an -tiprogestin treatment.
Fil: Pataccini, Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Vanzulli, Silvia. Academia Nacional de Medicina de Buenos Aires; Argentina
Fil: Lanari, Claudia Lee Malvina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Giulianelli, Sebastian Jesus. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Centro Nacional Patagónico. Instituto de Biología de Organismos Marinos; Argentina
Buenos Aires Breast Cancer Symposium
en línea
Argentina
Instituto de Fisiología, Biología Molecular y Neurociencias
Instituto de Biología y Medicina Experimental
Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno”
Instituto de Investigación en Medicina Traslacional
Instituto de Nanosistemas
Materia
CELL CYCLE INHIBITOR
PROGESTERONE RECEPTOR ISOFORM A
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/257740
Acceder
id CONICETDig_bc4b1efdbf9c874be5dec721b06c650f
oai_identifier_str oai:ri.conicet.gov.ar:11336/257740
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling CDK4/6 inhibitors and antiprogestins: therapeutic combination in breast cancer experimental models with high levels of progesterone receptor isoform APataccini, GabrielaVanzulli, SilviaLanari, Claudia Lee MalvinaGiulianelli, Sebastian JesusCELL CYCLE INHIBITORPROGESTERONE RECEPTOR ISOFORM Ahttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Luminal breast cancers are susceptible to an endocrine therapy. Palbociclib (PALBO), a CDK 4/6 inhibitor, is cur-rently used in combination with endocrine therapy to treat advanced hormone receptor-positive breast cancer (BC). However, with time patients acquire resistance. Therefore, alternative therapies are required to reduce BC mortality. We have recently reported that BC patients with tumors expressing higher levels of isoform A of the progesterone re-ceptor (PRA) than isoform B (PRB) may benefit from an an -tiprogestin treatment.Fil: Pataccini, Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Vanzulli, Silvia. Academia Nacional de Medicina de Buenos Aires; ArgentinaFil: Lanari, Claudia Lee Malvina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Giulianelli, Sebastian Jesus. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Centro Nacional Patagónico. Instituto de Biología de Organismos Marinos; ArgentinaBuenos Aires Breast Cancer Symposiumen líneaArgentinaInstituto de Fisiología, Biología Molecular y NeurocienciasInstituto de Biología y Medicina ExperimentalCentro de Educación Médica e Investigaciones Clínicas “Norberto Quirno”Instituto de Investigación en Medicina TraslacionalInstituto de NanosistemasFundación Revista Medicina2021info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjectSimposioJournalhttp://purl.org/coar/resource_type/c_5794info:ar-repo/semantics/documentoDeConferenciaapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/257740CDK4/6 inhibitors and antiprogestins: therapeutic combination in breast cancer experimental models with high levels of progesterone receptor isoform A; Buenos Aires Breast Cancer Symposium; en línea; Argentina; 2021; 15-150025-76801669-9106CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://ba-bcsymposium.com/program/info:eu-repo/semantics/altIdentifier/url/https://www.medicinabuenosaires.com/PMID/34673503.pdfInternacionalinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:58:28Zoai:ri.conicet.gov.ar:11336/257740instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:58:28.356CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv CDK4/6 inhibitors and antiprogestins: therapeutic combination in breast cancer experimental models with high levels of progesterone receptor isoform A
title CDK4/6 inhibitors and antiprogestins: therapeutic combination in breast cancer experimental models with high levels of progesterone receptor isoform A
spellingShingle CDK4/6 inhibitors and antiprogestins: therapeutic combination in breast cancer experimental models with high levels of progesterone receptor isoform A
Pataccini, Gabriela
CELL CYCLE INHIBITOR
PROGESTERONE RECEPTOR ISOFORM A
title_short CDK4/6 inhibitors and antiprogestins: therapeutic combination in breast cancer experimental models with high levels of progesterone receptor isoform A
title_full CDK4/6 inhibitors and antiprogestins: therapeutic combination in breast cancer experimental models with high levels of progesterone receptor isoform A
title_fullStr CDK4/6 inhibitors and antiprogestins: therapeutic combination in breast cancer experimental models with high levels of progesterone receptor isoform A
title_full_unstemmed CDK4/6 inhibitors and antiprogestins: therapeutic combination in breast cancer experimental models with high levels of progesterone receptor isoform A
title_sort CDK4/6 inhibitors and antiprogestins: therapeutic combination in breast cancer experimental models with high levels of progesterone receptor isoform A
dc.creator.none.fl_str_mv Pataccini, Gabriela
Vanzulli, Silvia
Lanari, Claudia Lee Malvina
Giulianelli, Sebastian Jesus
author Pataccini, Gabriela
author_facet Pataccini, Gabriela
Vanzulli, Silvia
Lanari, Claudia Lee Malvina
Giulianelli, Sebastian Jesus
author_role author
author2 Vanzulli, Silvia
Lanari, Claudia Lee Malvina
Giulianelli, Sebastian Jesus
author2_role author
author
author
dc.subject.none.fl_str_mv CELL CYCLE INHIBITOR
PROGESTERONE RECEPTOR ISOFORM A
topic CELL CYCLE INHIBITOR
PROGESTERONE RECEPTOR ISOFORM A
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv Luminal breast cancers are susceptible to an endocrine therapy. Palbociclib (PALBO), a CDK 4/6 inhibitor, is cur-rently used in combination with endocrine therapy to treat advanced hormone receptor-positive breast cancer (BC). However, with time patients acquire resistance. Therefore, alternative therapies are required to reduce BC mortality. We have recently reported that BC patients with tumors expressing higher levels of isoform A of the progesterone re-ceptor (PRA) than isoform B (PRB) may benefit from an an -tiprogestin treatment.
Fil: Pataccini, Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Vanzulli, Silvia. Academia Nacional de Medicina de Buenos Aires; Argentina
Fil: Lanari, Claudia Lee Malvina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Giulianelli, Sebastian Jesus. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Centro Nacional Patagónico. Instituto de Biología de Organismos Marinos; Argentina
Buenos Aires Breast Cancer Symposium
en línea
Argentina
Instituto de Fisiología, Biología Molecular y Neurociencias
Instituto de Biología y Medicina Experimental
Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno”
Instituto de Investigación en Medicina Traslacional
Instituto de Nanosistemas
description Luminal breast cancers are susceptible to an endocrine therapy. Palbociclib (PALBO), a CDK 4/6 inhibitor, is cur-rently used in combination with endocrine therapy to treat advanced hormone receptor-positive breast cancer (BC). However, with time patients acquire resistance. Therefore, alternative therapies are required to reduce BC mortality. We have recently reported that BC patients with tumors expressing higher levels of isoform A of the progesterone re-ceptor (PRA) than isoform B (PRB) may benefit from an an -tiprogestin treatment.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/conferenceObject
Simposio
Journal
http://purl.org/coar/resource_type/c_5794
info:ar-repo/semantics/documentoDeConferencia
status_str publishedVersion
format conferenceObject
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/257740
CDK4/6 inhibitors and antiprogestins: therapeutic combination in breast cancer experimental models with high levels of progesterone receptor isoform A; Buenos Aires Breast Cancer Symposium; en línea; Argentina; 2021; 15-15
0025-7680
1669-9106
CONICET Digital
CONICET
url http://hdl.handle.net/11336/257740
identifier_str_mv CDK4/6 inhibitors and antiprogestins: therapeutic combination in breast cancer experimental models with high levels of progesterone receptor isoform A; Buenos Aires Breast Cancer Symposium; en línea; Argentina; 2021; 15-15
0025-7680
1669-9106
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://ba-bcsymposium.com/program/
info:eu-repo/semantics/altIdentifier/url/https://www.medicinabuenosaires.com/PMID/34673503.pdf
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.coverage.none.fl_str_mv Internacional
dc.publisher.none.fl_str_mv Fundación Revista Medicina
publisher.none.fl_str_mv Fundación Revista Medicina
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269521800331264
score 13.13397

Publicaciones similares